Jazz Pharmaceuticals’ Epidyolex (cannabidiol) Receives NICE Recommendation for the Reimbursement to Treat Seizures in England
- NICE has been recommended for reimbursement of Epidyolex (cannabidiol, 100mg/mL oral solution) as adjunctive therapy for patients aged ≥2yrs. with seizures associated with tuberous sclerosis complex (TSC)
- This recommendation ensures that starting on Mar 2023, all eligible UK patients who might benefit from this medication will be able to receive reimbursed access to Epidyolex
- The therapy has been approved for use in the UK under three conditions & also been approved in the EU. The therapy also received marketing authorization under the trade name Epidyolex as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome or Dravet syndrome in conjunction with clobazam
Ref: Jazz Pharma | Image: Jazz Pharma
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.